SUSPENSION LETTER - MAILED
mailed
on 18 Jul 2024
Last Applicant/ Owned by
405-6190 Agronomy Road
Vancouver, B.C.
CA
V6T1Z3
Serial Number
97915885 filed on 01st May 2023
Registration Number
N/A
Correspondent Address
Karen Won
Filing Basis
1. intent to use
2. intent to use current
3. filed as use application
4. use application currently
Disclaimer
NO DATA
ACUITAS THERAPEUTICS
Research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; synthetic chemistry services, namely, design, synthes Read More
Classification Information
Class [045]
Personal & Legal & Social Services
Regulatory compliance consultancy services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid nanoparticles, nucleic acid, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology
First Use Date in General
18th Oct 2013
First Use Date in Commerce
18th Oct 2013
Class [042]
Computer & Software Services & Scientific Services
Research, development, and evaluation services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; synthetic chemistry services, namely, design, synthesis, analysis, evaluation, and biophysical characterization of lipids, lipid formulations, and lipid nanoparticles; preclinical study services, namely, conducting scientific feasibility studies, namely, pharmacodynamic and pharmacokinetic studies, scientific feasibility studies as to the human safety and tolerability studies regarding clinical pathology and histopathology, immune response characterization studies, and bioanalytical services in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, and nucleic acid therapeutics; scientific clinical research services, in the fields of chemical molecular analysis, pharmaceutical product optimization, and conducting clinical trial services for others in the field of pharmaceuticals; research and development of new formulation products for others, namely, vaccines and nucleic acid therapeutics; research and development for others in the fields of new pharmaceuticals, medical therapies, vaccines, gene therapies, drug delivery agents, and nucleic acid therapeutics for others; project management services for scientific research and development programs in the fields of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology; consultancy services in the fields of scientific research and development of pharmaceuticals, medical therapies, immunology, vaccines, biotechnology, nanotechnology, gene therapy, lipids, lipid formulations, lipid nanoparticles, nucleic acids, namely, messenger RNA, drug delivery agents, nucleic acid therapeutics, and synthetic chemistry process technology
First Use Date in General
18th Oct 2013
First Use Date in Commerce
18th Oct 2013
Class [005]
Pharmaceutical Products
Pharmaceutical preparations, namely, drug delivery agents in the nature of lipid nanoparticle carriers that facilitate delivery of pharmaceutical preparations and nucleic acid therapeutics as pharmaceutical preparations; pharmaceutical preparations comprised of nucleic acids, namely, messenger RNA and lipid nanoparticles for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders; pharmaceutical preparations, namely, vaccines for human use for treating cancer, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders, genetic disorders, allergy; pharmaceutical preparations for gene silencing, for gene editing, for antibody therapeutics, for protein replacement therapeutics, and for nucleic acid therapeutics, for treating cancer, genetic disorders, infectious diseases, cardiovascular diseases, liver diseases, autoimmune disorders, neurological disorders, metabolic disorders
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Lipids used in the manufacture of cosmetics, beverages, food products and food supplements, lipid nanoparticles used in the manufacture of cosmetics, beverages, food products, and food supplements, lipid formulations used in the manufacture of cosmetics, beverages, food products, and food supplements; nucleic acids, namely, messenger RNA, for scientific purposes, research laboratory use
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97915885
Mark Type
No Service Mark
Attorney Docket Number
No 062994-400
44D Filed
Yes
44D Current
Yes
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 17th Dec 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 17th Dec 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 17th Dec 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 17th Dec 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 17th Dec 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 18th Oct 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 18th Oct 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 18th Oct 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 18th Jul 2024 | SUSPENSION LETTER WRITTEN |
| 18th Jul 2024 | EXAMINER'S AMENDMENT ENTERED |